These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9690201)

  • 21. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
    Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
    Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.
    Benigni A; Colosio V; Brena C; Bruzzi I; Bertani T; Remuzzi G
    Diabetes; 1998 Mar; 47(3):450-6. PubMed ID: 9519753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
    Vaněčková I; Kujal P; Husková Z; Vaňourková Z; Vernerová Z; Certíková Chábová V; Skaroupková P; Kramer HJ; Tesař V; Červenka L
    Kidney Blood Press Res; 2012; 35(5):382-92. PubMed ID: 22487948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.
    Ortmann J; Amann K; Brandes RP; Kretzler M; Münter K; Parekh N; Traupe T; Lange M; Lattmann T; Barton M
    Hypertension; 2004 Dec; 44(6):974-81. PubMed ID: 15545511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.
    Benigni A; Zoja C; Zatelli C; Corna D; Longaretti L; Rottoli D; Maggioni P; Todeschini M; Noris M; Remuzzi G
    Kidney Int; 2004 Nov; 66(5):1959-65. PubMed ID: 15496167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes.
    Gross ML; Heiss N; Weckbach M; Hansen A; El-Shakmak A; Szabo A; Münter K; Ritz E; Amann K
    Diabetologia; 2004 Feb; 47(2):316-24. PubMed ID: 14727024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
    Schiffrin EL; Turgeon A; Deng LY
    Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation.
    Barton M; Shaw S; d'Uscio LV; Moreau P; Lüscher TF
    Biochem Biophys Res Commun; 1997 Sep; 238(3):861-5. PubMed ID: 9325182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
    Wolf SC; Sauter G; Risler T; Brehm BR
    Ren Fail; 2005; 27(4):465-74. PubMed ID: 16060137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
    Peters H; Border WA; Noble NA
    Kidney Int; 2000 Apr; 57(4):1493-501. PubMed ID: 10760085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heymann nephritis.
    Remuzzi A; Monaci N; Bonassi ME; Corna D; Zoja C; Mohammed EI; Remuzzi G
    Lab Invest; 1999 Dec; 79(12):1501-10. PubMed ID: 10616201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252.
    Bauersachs J; Braun C; Fraccarollo D; Widder J; Ertl G; Schilling L; Kirchengast M; Rohmeiss P
    J Hypertens; 2000 Oct; 18(10):1507-14. PubMed ID: 11057440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations.
    Verhagen AM; Braam B; Boer P; Gröne HJ; Koomans HA; Joles JA
    Kidney Int; 1999 Jul; 56(1):222-31. PubMed ID: 10411696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of angiotensin II in experimental membranous nephropathy.
    Gabbai FB; Wilson CB; Blantz RC
    Am J Physiol; 1988 Apr; 254(4 Pt 2):F500-6. PubMed ID: 2833120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
    Kirchengast M
    J Hypertens Suppl; 1997 Mar; 15(2):S27-33. PubMed ID: 9218195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
    Bakris GL; Weir MR; DeQuattro V; McMahon FG
    Kidney Int; 1998 Oct; 54(4):1283-9. PubMed ID: 9767545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.